
Buy Vesilute Research Peptide
Supplied as a lyophilised powder and independently verified to ≥98% purity by HPLC and MS-UPLC analysis. A batch-specific Certificate of Analysis is included with every order.

Buy Vesilute Research Peptide
Supplied as a lyophilised powder and independently verified to ≥98% purity by HPLC and MS-UPLC analysis. A batch-specific Certificate of Analysis is included with every order.
HPLC Verified
≥98% purity
Lyophilised
Powder format
Express Shipping
Cold-chain included
COA Included
Every batch
Ships Next Day
Order before midnight. Dispatched tomorrow with cold-chain packaging
HPLC Verified
≥98% purity
Lyophilised
Powder format
Express Shipping
Cold-chain included
COA Included
Every batch
Ships Next Day
Order before midnight. Dispatched tomorrow with cold-chain packaging
Vesilute is a synthetic dipeptide bioregulator with a molecular weight of 262.2 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesilute was designed based on peptide fractions associated with urinary bladder and vesical tissue. As one of the shortest peptides in the Khavinson bioregulator catalogue, it represents the minimal dipeptide unit investigated for organ-specific gene expression modulation within this research framework. Like other Khavinson bioregulators, Vesilute is proposed to exert its biological activity through direct interaction with DNA rather than cell surface receptor-mediated signalling. Produced via solid-phase peptide synthesis, Vesilute is associated with bladder tissue gene expression and urogenital signalling pathways.
Vesilute is an organ-specific dipeptide bioregulator targeting vesical tissue within the Khavinson framework. Its proposed mode of action is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1], and this direct-to-DNA principle of short-peptide control over tissue-specific gene expression has since been consolidated in a systematic review of the field [2]. Within that framework, Vesilute is studied as a vesical-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [3], making Vesilute a reference compound in preclinical bioregulation research examining vesical tissue specificity, short-peptide/DNA interaction models, and age-associated regulation of organ-specific gene expression.
Vesilute is manufactured in a cGMP compliant, ISO9001 certified laboratory to a guaranteed purity of 98% or above. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.
Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.
References
Editorial Team

Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer
Reviewed and approved 14 June 2026
What Researchers Say
Sign in to leave a reviewNo reviews yet. Be the first to share your research experience.
Frequently Asked Questions
Select Size
Buy 5+ vials to unlock discounts
Quality Guaranteed
Every batch is HPLC-tested to ≥99% purity. Certificate of Analysis and MSDS available with every order.
